Latest Insider Transactions at Fate Therapeutics Inc (FATE)
This section provides a real-time view of insider transactions for Fate Therapeutics Inc (FATE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of FATE THERAPEUTICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of FATE THERAPEUTICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 22
2022
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,246
+1.41%
|
$12,492
$2.7 P/Share
|
|
Jul 21
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-3.3%
|
$960,000
$32.81 P/Share
|
|
Jul 21
2022
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.1%
|
$60,000
$2.7 P/Share
|
|
Jul 07
2022
|
Bahram Valamehr President and CEO |
SELL
Open market or private sale
|
Direct |
17,158
-8.71%
|
$514,740
$30.23 P/Share
|
|
Jul 07
2022
|
Bahram Valamehr President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,158
+8.01%
|
$34,316
$2.73 P/Share
|
|
Jul 06
2022
|
Bahram Valamehr President and CEO |
SELL
Open market or private sale
|
Direct |
7,842
-4.18%
|
$235,260
$30.07 P/Share
|
|
Jul 06
2022
|
Bahram Valamehr President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,842
+2.05%
|
$23,526
$3.79 P/Share
|
|
Jul 05
2022
|
Mark Plavsic Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
3,719
-2.84%
|
$89,256
$24.61 P/Share
|
|
Jun 27
2022
|
Brian T. Powl Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+50.0%
|
-
|
|
Jun 09
2022
|
Shefali Agarwal |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+45.19%
|
-
|
|
Jun 09
2022
|
Timothy Coughlin |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+46.65%
|
-
|
|
Jun 09
2022
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+44.8%
|
-
|
|
Jun 09
2022
|
Karin Jooss |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+46.76%
|
-
|
|
Jun 09
2022
|
John Mendlein |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+4.93%
|
-
|
|
Jun 09
2022
|
William H Rastetter |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+43.29%
|
-
|
|
Jun 09
2022
|
Yuan Xu |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+39.24%
|
-
|
|
Jun 09
2022
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+43.29%
|
-
|
|
Jun 09
2022
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
8,650
+0.07%
|
-
|
|
Jun 09
2022
|
Robert S Epstein |
BUY
Grant, award, or other acquisition
|
Direct |
8,650
+43.29%
|
-
|
|
Jun 07
2022
|
Shefali Agarwal |
SELL
Open market or private sale
|
Direct |
841
-31.37%
|
$17,661
$21.89 P/Share
|
|
Jun 03
2022
|
Shefali Agarwal |
SELL
Open market or private sale
|
Direct |
807
-30.1%
|
$17,754
$22.8 P/Share
|
|
Jun 03
2022
|
Timothy Coughlin |
SELL
Open market or private sale
|
Direct |
1,439
-2.44%
|
$31,658
$22.81 P/Share
|
|
Jun 03
2022
|
Robert Hershberg Director |
SELL
Open market or private sale
|
Direct |
672
-25.07%
|
$14,784
$22.75 P/Share
|
|
Jun 03
2022
|
Karin Jooss |
SELL
Open market or private sale
|
Direct |
1,483
-55.32%
|
$32,626
$22.82 P/Share
|
|
Jun 03
2022
|
John Mendlein |
SELL
Open market or private sale
|
Direct |
1,364
-0.86%
|
$30,008
$22.79 P/Share
|
|
Jun 01
2022
|
Cindy Tahl |
SELL
Open market or private sale
|
Direct |
25,000
-11.67%
|
$550,000
$22.96 P/Share
|
|
Jun 01
2022
|
Cindy Tahl |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+10.45%
|
$150,000
$6.55 P/Share
|
|
Apr 22
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-1.13%
|
$340,000
$34.85 P/Share
|
|
Apr 22
2022
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.21%
|
$20,000
$2.7 P/Share
|
|
Apr 21
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-1.65%
|
$1,080,000
$36.23 P/Share
|
|
Apr 21
2022
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.1%
|
$60,000
$2.7 P/Share
|
|
Apr 19
2022
|
Yu Waye Chu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,062
-2.62%
|
$142,170
$35.37 P/Share
|
|
Apr 01
2022
|
Cindy Tahl |
SELL
Open market or private sale
|
Direct |
25,000
-11.67%
|
$950,000
$38.85 P/Share
|
|
Apr 01
2022
|
Cindy Tahl |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+5.53%
|
$125,000
$5.7 P/Share
|
|
Mar 14
2022
|
Bahram Valamehr President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-2.53%
|
$800,000
$32.37 P/Share
|
|
Mar 14
2022
|
Bahram Valamehr President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+10.88%
|
$50,000
$2.73 P/Share
|
|
Mar 10
2022
|
John Mendlein |
SELL
Open market or private sale
|
Direct |
31,562
-8.62%
|
$1,104,670
$35.11 P/Share
|
|
Mar 10
2022
|
John Mendlein |
BUY
Exercise of conversion of derivative security
|
Direct |
31,562
+14.18%
|
$31,562
$1.63 P/Share
|
|
Jan 25
2022
|
Cindy Tahl |
BUY
Grant, award, or other acquisition
|
Direct |
33,302
+14.97%
|
-
|
|
Jan 25
2022
|
Edward J Dulac Iii Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,302
+19.0%
|
-
|
|
Jan 25
2022
|
Mark Plavsic Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,302
+20.29%
|
-
|
|
Jan 25
2022
|
Yu Waye Chu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,302
+17.68%
|
-
|
|
Jan 25
2022
|
Bahram Valamehr President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
33,302
+15.62%
|
-
|
|
Jan 21
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.26%
|
$380,000
$38.02 P/Share
|
|
Jan 21
2022
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.21%
|
$20,000
$2.7 P/Share
|
|
Jan 20
2022
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-6.5%
|
$1,200,000
$40.21 P/Share
|
|
Jan 20
2022
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.1%
|
$60,000
$2.73 P/Share
|
|
Jan 11
2022
|
Yu Waye Chu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,965
-1.58%
|
$190,320
$48.77 P/Share
|
|
Jan 11
2022
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,770
-0.8%
|
$84,960
$48.71 P/Share
|
|
Jan 11
2022
|
Bahram Valamehr President and CEO |
SELL
Open market or private sale
|
Direct |
4,570
-1.52%
|
$219,360
$48.78 P/Share
|